Blog
RSS FeedPosted by Michael Wonder on 04 Sep 2017
At $475,000, new cancer drug raises thorny questions about drug pricing — and value
4 September 2017 - A first-of-its-kind cancer treatment is generating unbridled excitement — but also underscoring intense concerns over pricing ...
Posted by Michael Wonder on 01 Sep 2017
Novartis CEO's dilemma: is $475,000 too much for a leukaemia breakthrough? Or is it not enough?
30 August 2017 - Joseph Jimenez, the chief executive of Novartis, is celebrating a triumph. The Food and Drug Administration approved ...
Posted by Michael Wonder on 01 Sep 2017
A $475,000 price tag for a new cancer drug: crazy or meh?
31 August 2017 - Forget McGregor-Mayweather. The biotech world has been waiting for months to hear about Novartis’s pricing decision ...
Posted by Michael Wonder on 01 Sep 2017
Profit on $475,000 Novartis cancer drug could be a while coming
31 August 2017 - Novartis’s new gene-modifying cancer therapy’s $475,000-per-patient sticker price has drawn fire from advocate groups calling for ...
Posted by Michael Wonder on 31 Aug 2017
Is $475,000 too high a price for Novartis’s ‘historic’ cancer gene therapy?
31 August 2017 - On Wednesday, Swiss pharmaceutical giant Novartis made history as the first company to win FDA approval ...
Posted by Michael Wonder on 31 Aug 2017
A cancer doctor weighs in on CAR-T, precision medicine and pricing debates
31 August 2017 - Yesterday’s historic FDA approval of the first engineered T-cell treatment for cancer, Novartis’ Kymriah (tisagenlecleucel), was accompanied ...
Posted by Michael Wonder on 30 Aug 2017
Novartis gene therapy approval signals new cancer treatment era
30 August 2017 - Novartis AG on Wednesday won highly anticipated U.S. approval for the first of a new type ...
Posted by Michael Wonder on 29 Aug 2017
New drug price questions loom after Gilead's cancer purchase
29 August 2017 - Analysts say Kite’s therapy could reach $500,000 for one dose. ...
Posted by Michael Wonder on 28 Aug 2017
A new Parkinson’s drug is a long-acting version of a cheap generic. Should it cost $30,000 a year?
25 August 2017 - Adamas Pharmaceuticals had five minutes on Thursday night to feel good about its first U.S. drug ...
Posted by Michael Wonder on 23 Aug 2017
Breakthrough cancer drug could be astronomical in price
22 August 2017 - A new leukaemia drug being hailed by doctors as a breakthrough could prove among the most ...
Posted by Michael Wonder on 22 Aug 2017
Novartis CEO opens door to cancer patient demanding ‘fair’ CAR-T pricing
21 August 2017 - David Mitchell had just finished a five-hour infusion of drugs to keep his multiple myeloma under ...
Posted by Michael Wonder on 26 Jul 2017
Trump's FDA Commissioner on drug prices, regulations, science
25 July 2017 - U.S. FDA Commissioner Scott Gottlieb spoke with Bloomberg News about drug pricing, new medicine and regulations. ...
Posted by Michael Wonder on 28 Jun 2017
FDA commissioner takes on Martin Shkreli-wannabes over huge drug price hikes
28 June 2017 - "We don't play a role in drug pricing, but we do affect drug competition," Dr. Scott Gottlieb ...
Posted by Michael Wonder on 27 Jun 2017
FDA tackles drug competition to improve patient access
27 June 2017 - Agency takes important steps under new Drug Competition Action Plan. ...
Posted by Michael Wonder on 12 Jun 2017
Drug prices: this time is different
11 June 2017 - Yet another congressional hearing on drug prices is on tap. Investors should resist the temptation to ...